The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization

• Published in: The Journal of asthma Vol. 57; no. 10; pp. 1092 - 1102
• Main Authors: Viinanen, A., Lassenius, M. I., Toppila, I., Karlsson, A., Veijalainen, L., Idänpään-Heikkilä, J. J., Laitinen, T.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.10.2020
• Subjects: Adult; Aged; Aged, 80 and over; Anti-Asthmatic Agents - therapeutic use; Asthma - drug therapy; Asthma - economics; Asthma - epidemiology; Asthma - physiopathology; Body Mass Index; Cost of Illness; Costs and Cost Analysis; Eosinophilia - epidemiology; Eosinophils - metabolism; Female; Finland; health care costs; health care resource utilization; Health Expenditures - statistics & numerical data; Health Resources - economics; Health Resources - statistics & numerical data; Humans; Male; Middle Aged; mortality; Patient Acceptance of Health Care - statistics & numerical data; Retrospective Studies; Severe asthma; severe eosinophilic asthma; Severity of Illness Index; Finland; mortality; Severe asthma; severe eosinophilic asthma; health care costs; health care resource utilization
• ISSN: 0277-0903; 1532-4303
• DOI: 10.1080/02770903.2019.1633664

Objective: To describe health care resource utilization (HCRU) and associated costs in adult patients referred for specialist asthma care in Southwest Finland, by disease severity and blood eosinophil count (BEC). Methods: This non-interventional, retrospective registry study (GSK ID: HO-17-17558) utilized data from patients >18 years of age on the hospital register of the Hospital District of Southwest Finland. Data extraction was from January 1, 2004 to December 31, 2015; the index date was the first hospital visit within this period with an International Classification of Diseases-10 diagnosis code for asthma or acute severe asthma. Patients were categorized by asthma severity (based on medication use) and BEC (<300 or ≥300 cells/μL). Total and asthma-related HCRU and estimated costs were recorded the year following index and for calendar years 2004-2015. Results: Overall, 14,398 patients were included; 388 had severe asthma at index. BEC was available for 3781 patients; 1434 had a BEC ≥300 cells/μL and 2347 had a BEC <300 cells/μL. A total of 1241 patients had severe asthma; 270 patients had severe eosinophilic asthma (severe asthma and a BEC ≥300 cells/μL). Patients with severe versus non-severe asthma had higher total- and asthma-related outpatient visits, inpatient days, emergency room visits and costs per patient year; those with BEC ≥300 cells/μL versus <300 cells/μL had more outpatient visits. All recorded HCRU and associated costs were highest in patients with severe eosinophilic asthma. Conclusion: This study demonstrated a substantial burden associated with severe and/or eosinophilic asthma for adults in Finland.